Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metaxalone
Drug ID BADD_D01400
Description Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.
Indications and Usage For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
Marketing Status Prescription; Discontinued
ATC Code Not Available
DrugBank ID DB00660
KEGG ID D00773
MeSH ID C011301
PubChem ID 15459
TTD Drug ID D0S5CH
NDC Product Code 63629-2398; 71205-961; 63187-490; 75945-070; 71335-1320; 55111-650; 71205-426; 50090-3650; 0185-0448; 71205-326; 60793-136; 80425-0084; 69306-100; 72789-028; 71335-2066; 70518-2275; 43826-136; 68001-004; 55289-736; 71335-0958; 45865-942; 68788-7018; 61919-091; 72789-122; 52076-6231; 0904-6831; 0115-1748; 53746-553; 54871-1087; 10920-581; 63629-8014; 65977-0089; 71205-470; 73680-0011; 70934-160; 47621-020; 12666-0012; 50268-530; 70518-0771; 61919-832; 45865-985; 63629-2097; 50056-1999; 68084-135; 65162-553; 50228-474; 60760-289; 67296-1778; 55700-494; 70518-0818; 69306-311; 80425-0131; 50090-3670; 71335-0186; 50228-323; 71335-0099; 43826-126; 64980-472; 67296-1275; 42291-587; 55700-911; 0276-0508; 0115-1745; 67296-1577; 67296-0993; 68001-485; 68788-7499; 71205-016; 50090-3174; 0527-1435; 60760-093; 50090-4448; 61919-346; 80425-0122; 0591-2341; 68788-7675
Synonyms metaxalone | Skelaxin | AHR 438
Chemical Information
Molecular Formula C12H15NO3
CAS Registry Number 1665-48-1
SMILES CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal pain07.01.05.0020.001489%
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angioedema10.01.05.009; 23.04.01.0010.001489%Not Available
Anxiety19.06.02.002--
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.0040.000993%
Blood glucose increased13.02.02.0020.000993%Not Available
Cardiac arrest02.03.04.0010.000389%
Clonus17.02.05.0020.000993%Not Available
Coma17.02.09.0010.001036%Not Available
Completed suicide08.04.01.010; 19.12.01.0010.001295%Not Available
Death08.04.01.001--
Delirium19.13.02.0010.000518%
Depressed level of consciousness17.02.04.0020.000907%
Dermatitis23.03.04.002--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.02.0100.000259%Not Available
Drug hypersensitivity10.01.01.0010.042693%Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Electrocardiogram QT prolonged13.14.05.0040.000648%
Fatigue08.01.01.002--
Haemolytic anaemia01.06.03.002--Not Available
Headache17.14.01.0010.002482%
Heart rate increased13.14.04.0020.000993%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.001489%
Hyperreflexia17.02.01.0020.000518%Not Available
Hypersensitivity10.01.03.0030.000993%
Hypertension24.08.02.0010.001986%
The 1th Page    1 2 3    Next   Last    Total 3 Pages